Unicycive Therapeutics Inc (UNCY) USD0.001

Sell:$0.60Buy:$0.62$0.02 (2.88%)

Prices delayed by at least 15 minutes
Sell:$0.60
Buy:$0.62
Change:$0.02 (2.88%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.60
Buy:$0.62
Change:$0.02 (2.88%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

Key people

Shalabh Gupta
Chairman of the Board, President, Chief Executive Officer, Founder
John Townsend
Chief Financial Officer
Pramod Gupta
Executive Vice President - Pharmaceutical and Business Operations
Doug Jermasek
Executive Vice President, Corporate Strategy
Gaurav Aggarwal
Independent Director
Saraswati Kenkare-Mitra
Independent Director
Sandeep Laumas
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US90466Y1038
  • Market cap
    $62.28m
  • Employees
    14
  • Shares in issue
    103.80m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.